Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24 months follow-up study
Luca D’Onofrio, Carmen Mignogna, Angela Carlone, Ermanno Bellizzi, Michela Guida, Chiara Moretti, Simona Zampetti, Gaetano Leto, Ernesto Maddaloni, Raffaella Buzzetti
Topics & Concepts
MedicineInternal medicineDiabetes mellitusType 2 diabetesFramingham Risk ScoreCoronary heart diseaseType 2 Diabetes MellitusLower riskDiseaseEndocrinologyConfidence intervalDiabetes Treatment and ManagementCancer Research and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins